2021年5月31日 星期一

【中/ENG】國民黨:未反對國產疫苗 但切勿倉促上路 The KMT: We Don’t Oppose the Domestically-produced Vaccine Insofar as It Isn't Rushed through Clinical Trials.

             新 聞 稿      中國國民黨文化傳播委員會 110.05.31


國民黨:未反對國產疫苗 但切勿倉促上路


針對蔡英文總統今(31)日發表防疫進度、疫苗發展相關談話,國民黨表示,台灣疫情仍嚴峻,疫苗嚴重不足,國人都希望在最快時間內打到疫苗,請蔡總統明確回答國人,台灣何時能達到七成疫苗施打率?具體到貨的疫苗數量與施打期程為何?若無法給予人民明確保證,人民還是會持續焦慮,無法得到疫苗保護。也呼籲蔡總統,應制止民進黨部分人士一再以扭曲不實訊息誤導社會視聽,影響防疫工作。


國民黨指出,蔡總統通篇談話規避在野黨多項提問,只要大眾共同為政府澄清假訊息,但面對政府與民進黨近日被檢舉的大量假訊息卻沒有提出相關說法。國民黨亦質疑,當各國政府傾全力採購安全、有效的國際認證疫苗時,只有我們的政府認為「疫苗買夠了」,為何採購態度如此消極,目前僅到貨86萬劑疫苗,接種率淪為末段班,蔡總統應該給外界清楚的說明。


國民黨強調,並未反對國產疫苗,也肯定國內研發人員的努力,但絕不可為了倉促上路,簡化臨床實驗程序,應該進行三期試驗,證明疫苗有效性,不可拿國民健康作為賭注。任何疫苗,要在沒有國際認證下就要求國民施打,人民如何能夠安心?政府又如何能夠信誓旦旦的保證安全有效?


國民黨表示,稍早新加坡總理李顯龍同樣發表談話,卻可以看到清楚正視病毒更具傳染力事實,告知民眾將可自行購買新冠檢測工具、承諾更廣泛地進行檢測,以及定期檢測潛在超級傳播者等規劃讓國民安心。相較之下,蔡總統通篇內容缺乏對於疫苗施打的具體時程與確切政策規劃,記者會開完了,但是人民仍得不到想要的答案。 




The KMT: We Don’t Oppose the Domestically-produced Vaccine Insofar as It Isn't Rushed through Clinical Trials.


In response to President Tsai’s remarks today (May 31) on the progress of pandemic prevention and vaccine development, “Taiwan hasn’t been out of the Covid woods and is still facing a dire lack of vaccines,” says the Kuomintang (KMT). Taiwan’s citizens hope to receive the vaccine as soon as possible. And President Tsai must answer when Taiwan can achieve a 70% vaccination rate among its population. Further, the administration must disclose the exact amount of vaccine in storage and lay out a clear vaccination schedule. Without explicit assurances, our citizens will face continuous anxiety, remain exposed to Covid-19. The KMT also calls upon President Tsai to stop some members of the DPP from misleading the public with distorted and untrue information, which has hamstrung the pandemic prevention work.

The KMT notes President Tsai skirted many of the opposition’s questions throughout her remarks, taking the opportunity instead to implore the public to work together to stem and clarify fake information for the administration. Yet Ms. Tsai didn’t even bother to produce any statement on the recent controversy- accusation of disseminating an avalanche of fake news- swirling around her party and administration. Meanwhile, the KMT questions why our government considers our vaccine doses sufficient just when governments worldwide are striving mightily to purchase safe, effective and internationally certified vaccines. To date, Taiwan only has 860,000 vaccine doses in storage, with the vaccination rate being among the lowest. President Tsai should provide an explanation to the public.

The KMT stresses that it doesn’t oppose to the domestically-produced vaccine and recognizes the efforts invested in its research and development by our brilliant scientists and medical researchers. However, the clinical trials should not be simplified or shortened for the purpose of a faster rollout, thus the vaccine shouldn’t gain a green light until it passes the Phase 3 clinical trial. After all, our citizens’ health must be the highest of priorities. No matter which types of vaccines, how could the public feel safe to have vaccines injected in their arms that aren’t internationally certified? How could we make the people feel safe about the vaccine?

The KMT further points out that just like President Tsai, the Prime Minister of Singapore, Lee Hsien Loong, also made similar remarks earlier. The difference was that unlike President Tsai, Mr. Lee was willing to confront the reality that Covid-19 has now become ever-more contagious. Furthermore, Mr. Lee reassured the restive public by telling them they would be able to buy their testing kits, promising to deploy more extensive testing systems and regularly testing potential super-spreaders. In comparison, President Tsai’s litany was devoid of substance- lacking a reified vaccination schedule nor a specific plan for vaccination implementation. After Ms. Tsai’s press conference, myriad questions were unresolved, and Taiwan’s citizens were left scratching their heads.

(This is an abridged version of an official KMT Chinese language press release)
Tags :
分享至 Google Plus 分享至 Line 友善列印